Patents by Inventor Elinborg Ostermann

Elinborg Ostermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180186876
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: February 15, 2018
    Publication date: July 5, 2018
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • Patent number: 9932399
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 3, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • Publication number: 20160137729
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: April 22, 2015
    Publication date: May 19, 2016
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • Patent number: 9078879
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: July 14, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • Publication number: 20140010808
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: August 23, 2013
    Publication date: January 9, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • Publication number: 20140004110
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: August 23, 2013
    Publication date: January 2, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • Patent number: 8580254
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: November 12, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Elinborg Ostermann
  • Patent number: 8568727
    Abstract: Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: October 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Guenther Adolf, Elinborg Ostermann, Milena Kalat, Karl-Heinz Heider
  • Publication number: 20110165153
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: September 17, 2010
    Publication date: July 7, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz HEIDER, Eric BORGES, Elinborg OSTERMANN
  • Publication number: 20100196395
    Abstract: Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.
    Type: Application
    Filed: June 19, 2008
    Publication date: August 5, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Paul Adam, Elinborg Ostermann
  • Publication number: 20100189722
    Abstract: Chimeric and humanized anti-CD37 antibodies and pharmaceutical compositions containing them are useful for the treatment of B cell malignancies and autoimmune and inflammatory diseases that involve B cells in their pathology.
    Type: Application
    Filed: August 8, 2008
    Publication date: July 29, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Karl-Heinz Heider, Eric Borges, Elinborg Ostermann
  • Publication number: 20090304718
    Abstract: Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.
    Type: Application
    Filed: December 22, 2006
    Publication date: December 10, 2009
    Inventors: Guenther Adolf, Elinborg Ostermann, Milena Kalat, Karl-Heinz Heider
  • Patent number: 7417127
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: August 26, 2008
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Bohringer Ingelheim International GmbH
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Patent number: 6972324
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: December 6, 2005
    Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International, GmbH
    Inventors: G√ľnther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Publication number: 20050214212
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Application
    Filed: May 25, 2005
    Publication date: September 29, 2005
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John Miglietta, Augustinus Antonius Van Dongen
  • Patent number: 6759211
    Abstract: The present invention is generally directed to the identification of mouse and human genes that inhibit the growth of a tumor and induce apoptosis in cancer cells, and to polypeptides encoded by such genes. In particular, the invention concerns the nucleotide sequence of one such tumor-inhibiting gene, tag7, and the amino acid sequence of a polypeptide encoded by tag7. The invention also provides isolated nucleic acid molecules comprising tag7 polynucleotides, and vectors and host cells comprising these isolated nucleic acid molecules. The invention also provides methods of producing tag7 polynucleotides using these nucleic acid molecules, vectors and host cells, tag7 polypeptides made by three methods and antibodies that specifically bind to the tag7 polypeptide. The invention also concerns methods of inhibiting tumor growth and inducing tumor cell apoptosis, and methods of cancer therapy, using the present tag7 nucleic acid molecules and polypeptides.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: July 6, 2004
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Georgii Georgiev, Sergei Kiselev, Egor Prokhorchouk, Elinborg Ostermann
  • Publication number: 20030190319
    Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.
    Type: Application
    Filed: May 20, 2002
    Publication date: October 9, 2003
    Inventors: Gunther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
  • Publication number: 20020137670
    Abstract: Complex of DNA, containing one or more DNA molecules coding for one or more therapeutically active proteins with a cytotoxic activity, and a polycation conjugated with transferrin with a zeta potential of ≦+15 mV. The complex, in which a high transferrin content screens the positive charge, produces a targeted transportation of the therapeutic DNA to the tumors in the systemic treatment of tumor diseases.
    Type: Application
    Filed: October 3, 2001
    Publication date: September 26, 2002
    Applicant: Boehringer Ingelheim International GmbH.
    Inventors: Ralf Kircheis, Ernst Wagner, Lionel Wightman, Elinborg Ostermann
  • Patent number: 6172211
    Abstract: The present invention is generally directed to the identification of mouse and human genes that inhibit the growth of a tumor and induce apoptosis in cancer cells, and to polypeptides encoded by such genes. In particular, the invention concerns the nucleotide sequence of one such tumor-inhibiting gene, tag7, and the amino acid sequence of a polypeptide encoded by tag7. The invention also provides isolated nucleic acid molecules comprising tag7 polynucleotides, and vectors and host cells comprising these isolated nucleic acid molecules. The invention also provides methods of producing tag7 polypeptides using these nucleic acid molecules, vectors and host cells, tag7 polypeptides made by these methods and antibodies that specifically bind to the tag7 polypeptide. The invention also concerns methods of inhibiting tumor growth and inducing tumor cell apoptosis, and methods of cancer therapy, using the present tag7 nucleic acid molecules and polypeptides.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: January 9, 2001
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Georgii P. Georgiev, Sergei L. Kiselev, Egor B. Prokhorchouk, Elinborg Ostermann
  • Patent number: 5589371
    Abstract: The present invention relates to a method of preparing human Mn-superoxide dismutase (hMn-SOD) by genetic engineering, the DNA sequences which code for this enzyme, suitable vectors which contain these DNA sequences and host cells which can express these DNA sequences, and the enzyme hMn-SOD itself. Suggestions as to the use of this enzyme are also described.
    Type: Grant
    Filed: March 30, 1995
    Date of Patent: December 31, 1996
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Konrad Heckl, Walter Spevak, Elinborg Ostermann, Andreas Zophel, Edeltraud Krystek, Ingrid Maurer-Fogy, Maria J. Wiche-Castanon, Christian Stratowa, Rudolf Hauptmann